橙皮素及其衍生物抑制纤维化作用研究进展

doi:10.19803/j.1672-8629.2022.05.24

摘要/Abstract

摘要： 橙皮素是一种来源于芸香科柑橘属幼果的二氢黄酮化合物,对肺、肝、肾及心脏等器官的纤维化过程具有显著的抑制作用。但由于橙皮素抑制纤维化作用机制复杂,目前尚处于实验研究阶段,有待进一步研究。本文探讨了橙皮素对肺纤维化、肝纤维化、肾纤维化、心肌纤维化等疾病在抗炎、抗氧化应激、促进细胞凋亡、抑制细胞激活和增殖、抑制细胞上皮间质转化等方面的作用机制,阐述了橙皮素及其衍生物抑制纤维化的研究进展。为橙皮素开发成为靶向纤维化药物以及如何提高橙皮素的利用度提供一定的借鉴和帮助。

关键词: 橙皮素, 肺纤维化, 肝纤维化, 肾纤维化, 心肌纤维化

Abstract: Hesperetin is a dihydro flavonoid compound derived from young fruits of the Citrus in Rutaceae family,which has a significant inhibitory effect on the fibrosis process of lung, liver, kidney and heart. However, due to the complex mechanism of hesperetin inhibiting fibrosis, it is still in the experimental research stage and needs further study. This article explores the mechanism of hesperetin on pulmonary fibrosis, hepatic fibrosis, renal fibrosis, heart fibrosis and other diseases from the aspects of anti-inflammatory, anti-oxidative stress, promoting cell apoptosis, inhibiting cell activation and proliferation, and inhibiting cell epithelial-mesenchymal transition, and expounds that hesperetin and its derivatives inhibit fibrosis Research progress. It will provide some reference and help for the future development of hesperetin as a targeted fibrosis drug and how to improve the utilization of hesperetin.

Key words: hesperetin, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, heart fibrosis

中图分类号:

R994.11
R961

万微, 常军, 朱笃. 橙皮素及其衍生物抑制纤维化作用研究进展[J]. 中国药物警戒, 2022, 19(5): 579-584.

WAN Wei, CHANG Jun, ZHU Du, CHEN Wen. Research progress on hesperetin and its derivatives against fibrosis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 579-584.

参考文献

[1] IRANSHAHI M, REZAEE R, PARHIZ H, et al.Protective effects of flavonoids against microbes and toxins: the cases of hesperidin and hesperetin[J]. Life Sciences, 2015, 137: 125-132.
[2] LI R, CAI L, XIE XF, et al.7,3'-dimethoxy hesperetin inhibits inflammation by inducing synovial apoptosisin rats with adjuvant-induced arthritis[J]. Immunopharmacology & Immunotoxicology, 2013, 35(1): 139-146.
[3] PARHIZ H, ROOHBAKHSH A, SOLTANI F, et al.Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin:an updated review of their molecular mechanisms and experimental models[J]. Phytotherapy Research Ptr, 2015, 29(3): 323-331.
[4] LI L, REN ZX, ZHAO P, et al.Research progress in antitumor pharmacological activities of hesperidin and hesperetin[J]. Acta Chinese Medicine(中医学报), 2018, 33(12): 2304-2308.
[5] MIWA Y, MITSUZUMI H, SUNAYAMA T, et al.Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality[J]. Journal of Nutritional Science & Vitaminology, 2005, 51(6): 460-470.
[6] KHAN A, IKRAM M, HAHMJR, et al. Antioxidant and anti-inflammatory effects of citrus flavonoid hesperetin: special focus on neurological disorders[J]. Antioxidants, 2020, 9(7): 609-614.
[7] MULVIHILL EE, BURKE AC, HUFF MW.Citrus Flavonoids as regulators of lipoprotein metabolism and atherosclerosis[J]. Annual Review of Nutrition, 2016, 36(1): 275-299.
[8] LI S, SHAO L, FANG J, et al.Hesperetin attenuates silica induced lung injury by reducing oxidative damage and inflammatory response[J]. Experimental and Therapeutic Medicine, 2021, 21(4): 297-308.
[9] KONG R, WANG N, LUO H, et al.Hesperetin mitigates bile duct ligation-induced liver fibrosis by inhibiting extracellular matrix and cell apoptosis via the TGF-beta1/Smad Pathway[J]. Current Molecular Medicine, 2018, 18(1): 15-24.
[10] CHOI D, KIM CL, KIM J E, et al.Hesperetin inhibit EMT in TGF-beta treated podocyte by regulation of mTOR pathway[J]. Biochemical and Biophysical Research Communications, 2020, 528(1): 154-159.
[11] WANG B, LI LH, JIN P, et al.Hesperetin protects against inflammatory response and cardiac fibrosis in postmyocardial infarction mice by inhibiting nuclear factor kappaB signaling pathway[J]. Experimental and Therapeutic Medicine, 2017, 14(3): 2255-2260.
[12] HENDERSON NC, RIEDER F, WYNN TA.Fibrosis: from mechanisms to medicines[J].Nature, 2020, 587(7835): 555-566.
[13] ZEISBERG M, KALLURI R.Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis[J]. American Journal of Physiology Cell Physiology, 2013 304(3): 216-225.
[14] RAGHU G, ROCHWERG B, ZHANG Y, et al.An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2015, 192(2): e3-e19.
[15] ROBALO-CORDEIRO C, MORAIS A.Translating Idiopathic pulmonary fibrosis guidelines into clinical practice[J]. Pulmonology, 2021, 27(1): 7-13.
[16] SUBBIAH R, RAJAGURU P, SUDHAKAR G.MicroRNAs as potential targets for progressive pulmonary fibrosis[J]. Front Pharmacol, 2015, 11(6): 254-269.
[17] DAVID JL, FERNANDO JM.Idiopathic pulmonary fibrosis[J]. The New England Journal of Medicine, 2020, 378(19): 1811-1823.
[18] NOBLE PW, ALBERA C, BRADFORD WZ, et al.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials[J]. The Lancet, 2011, 377(9779): 1760-1769.
[19] WOLLIN L, WEX E, PAUTSCH A.et al.Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis[J]. The European Respiratory Journal, 2015, 45(5): 1434-1445.
[20] DUAN ZL, ZHOU R.Research progress of NF-κB in lung cancer[J]. Joural of Clinical and Pathological Research(临床与病理杂志), 2016, 36(3): 337-341.
[21] MA H, FENG X, DING S.Hesperetin attenuates ventilator-induced acute lung injury through inhibition of NF-kappaB-mediatedinflammation[J]. European Journal of Pharmacology, 2015, 11(769): 333-341.
[22] POLAT FR, DURAN Y, KARABOGA I, et al.Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury in a rat model[J]. Turkish Journal of Thoracic and Cardiovascular Surgery, 2020, 28(2): 359-368.
[23] PARK JH, KU HJ, PARK JW.Hesperetin mitigates acrolein-induced apoptosis in lung cells in vitro and in vivo[J]. Redox Report: Communications in Free Radical Research, 2018, 23(1): 188-193.
[24] JIANG Y, CHEN YQ, ZHANG J, et al.Antagonism of hesperidin to paraquat- induced oxidative stress in lung of rats[J]. Journal of Environment and Health(环境与健康杂志), 2018, 35(2): 133-137.
[25] REN Z, SHEN J, MEI X, et al.Hesperidin inhibits the epithelial to mesenchymal transition induced by transforming growth factor-β1 in A549 cells through Smad signaling in the cytoplasm[J]. Brazilian Journal of Pharmaceutical Sciences, 2019, 55(e18172): 1-9.
[26] MA QL, ZHANG LT, YANG WK, et al.Advances in the development of severe acute respiratory syndrome coronavirus 2 cell receptor ACE2[J]. Journal of Lanzhou Universit(兰州大学学报), 2020, 46(2): 70-75.
[27] LIN CW, TSAI FJ, TSAI CH, et al.Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds[J]. Antiviral Res. 2005, 68(1): 36-42.
[28] National Health Commission of the People's Republic of China.Notice on the Issuance of the Fifth trial version of the Diagnosis and Treatment Protocol for novel Coronavirus Pneumonia[EB/OL].(2020-02-04)[2021-08-09] http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
[29] HUANG C, WANG Y, REN L, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. The Lancet, 2020, 395(10223): 497-506.
[30] FAUCI AS, LANE HC, REDFIELD RR, et al.COVID-19 - Navigating the Uncharted[J]. The New England journal of medicine, 2020, 382(13): 1268-1269.
[31] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet,2020, 395(10223): 507-513.
[32] ARSHAD ALI S, BALOCH M, AHMED N, et al.The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat[J]. Journal of Infection and Public Health,2020, 13(4): 644-646.
[33] KOYAMA Y, XUJ, LIU X, et al.New Developments on the Treatment of Liver Fibrosis[J]. Digestive Diseases, 2016, 34(5): 589-596.
[34] ZHANG CY, YUAN WG, HE P, et al.Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets[J].World J Gastroenterol, 2016, 22(48): 10512-10522.
[35] SHENG CL.Protective effect of 8-methylene-tert-butylamine hesperetin (MTBH)on CCl₄-induced liver fibrosis in mice and its pharmacokinetic studies in rats[D]. Anhui Medical University, 2016.
[36] LI WX.Effects and mechanisms of Hesperitin derivative-11 on CCl₄-induced rat hepatic fibrosis[D]. Anhui Medical University, 2017.
[37] CHEN X,DING HW, LI HD, et al.Hesperetin derivative-14 alleviates inflammation by activating PPAR-gamma in mice with CCl₄-induced acute liver injury and LPS-treated RAW264.7 cells[J]. Toxicol Lett, 2017, 5(274): 51-63.
[38] ZHENG Y, ZHANG YL, ZENG L I, et al.Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice[J]. European Journal of Medicinal Chemistry, 2021, 3(213): 162-173.
[39] CHEN X, LI X F, CHEN Y, et al.Hesperetin derivative attenuates CCl₄-induced hepatic fibrosis and inflammation by Gli-1-dependent mechanisms[J]. International Immunopharmacology, 2019, 76: 105838.
[40] ELSHAZLY SM, MAHMOUD A.Antifibrotic activity of hesperidin against dimethylnitrosamine-induced liver fibrosis in rats[J]. Archiv für Experimentelle Pathologie und Pharmakologie, 2014, 387(6): 559-567.
[41] PÉREZ-VARGAS JE, ZARCO N, SHIBAYAMA M, et al. Hesperidin prevents liver fibrosis in rats by decreasing the expression of nuclear factor-kappaB, transforming growth factor-beta and connective tissue growth factor[J]. Pharmacology, 2014, 94(1): 80-89.
[42] WU F, JIANG L, HE X, et al.Effect of hesperidin on TGF-beta1/Smad signaling pathway in HSC[J]. China Journal of Chinese Materia Medica, 2015, 40(13): 2639-2643.
[43] LIN X, KONG LN, HUANG C, et al.Hesperetin derivative-7 inhibits PDGF-BB-induced hepatic stellate cell activation and proliferation by targeting Wnt/beta-catenin pathway[J]. International Immunopharmacology, 2015, 25(2): 311-320.
[44] QIU M, LI J, TAN L, et al.Targeted ablation of distal cerebrospinal fluid-contacting nucleus alleviates renal fibrosis in chronic kidney disease[J]. Frontiers in Physiology, 2018, 9(9): 1640-1650.
[45] KALLURI R, WEINBERG RA.The basics of epithelial-mesenchymal transition[J]. Journal of Clinical Investigation, 2015, 119(6): 1420-142.
[46] WANG HW, SHI L, XU YP, et al.Hesperetin alleviates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro[J]. Experimental & Therapeutic Medicine, 2017, 14(4): 3713-3719.
[47] YANG XL, QU H Y, RONG JF, et al.Research progress in pathogenesis of myocardial fibrosis[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2020, 18(14): 2255-2258.
[48] YIN Y, XU Y, MA H, et al.Hesperetin ameliorates cardiac inflammation and cardiac fibrosis in streptozotocin-induced diabetic rats by inhibiting NF-kappa B signaling pathway[J]. Biomedical Research-India, 2017, 28(1): 223-229.
[49] VELUSAMY P, MOHANT, RAVI DB, et al.Targeting the Nrf2/ARE signalling pathway to mitigate isoproterenol-induced cardiac hypertrophy: plausible role of hesperetin in redox homeostasis[J]. Oxidative Medicine and Cellular Longevity, 2020, (9568278): 1-13.
[50] DENG W, JIANG D, FANG Y, et al.Hesperetin protects against cardiac remodelling induced by pressure overload in mice[J]. Journal of Molecular Histology, 2013, 44(5): 575-585.
[51] YANG Z, LIU Y, DENG W, et al.Hesperetin attenuates mitochondria-dependent apoptosis in lipopolysaccharide-induced H9C2 cardiomyocytes[J]. Molecular Medicine Reports, 2014, 9(5): 1941-1946.